CHMP gives backing to J&J's Zytiga
This article was originally published in Scrip
Executive Summary
Experts on the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval, under an accelerated regulatory review procedure, of Janssen-Cilag's Zytiga (albiraterone acetate), in combination with prednisone or prednisolone, to treat patients with metastatic castration resistant prostate cancer who have received prior treatment with the chemotherapy agent docetaxel. In April, the FDA approved Zytiga for the same indication (scripintelligence.com, 2 May 2011).